+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 24 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and pharmacokinetics of SHR-4685 in adults with advanced solid tumors. This phase I study aims to determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of SHR-4685, helping to understand how the drug behaves in the body and its potential side effects. Participants will receive SHR-4685 in varying doses as part of a single treatment group. The study monitors participants for up to 24 months to assess adverse events, serious adverse events, and drug concentration levels in plasma. The treatment period includes regular assessments at predefined intervals to gather detailed pharmacokinetic data and observe tumor response measures. During the study, participants will undergo evaluations including tumor measurements based on RECIST 1.1 criteria, laboratory tests to monitor organ function and presence of antibodies against SHR-4685, and safety assessments to track side effects. Researchers will measure outcomes such as objective response rate, disease control rate, duration of response, and progression-free survival. Safety monitoring continues for 30 days after the last dose, and the total participation can last up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are evaluating HLX48, an EGFRc-MET bispecific antibody-drug conjugate, in patients with advanced or metastatic solid tumors. This open-label phase I clinical trial aims to assess the safety, tolerability, and pharmacokinetic profile of HLX48 given at increasing doses. The trial uses a 33 dose escalation design to carefully study the effects and side effects of HLX48 in this patient population. Participants will receive HLX48 via intravenous infusion at one of six preset dose levels. The dose-limiting toxicity DLT observation period lasts for 3 weeks after the first dose, during which the Safety Review Committee reviews safety data to decide on dose escalation or cohort expansion. New dose groups may be added based on safety, tolerability, pharmacokinetics, immunogenicity, and efficacy data. Those who withdraw early for reasons unrelated to toxicity may be replaced. Throughout the study, participants will undergo evaluations including tumor measurements by RECIST v1.1, ECOG performance status assessments, and laboratory tests to confirm organ function. Safety monitoring includes dose-limiting toxicity and maximum tolerated dose assessments within the first cycle of treatment. Secondary outcomes such as response rates, survival, and antibody development will be tracked for up to 24 months. Participants are followed closely during and after treatment to collect comprehensive data on HLX48s effects.

Age: 18Years - 75YearsAll GendersPhase 1
7 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor effects of AK138D1 in adults with advanced solid tumors. This first-in-human, open-label Phase I trial includes patients whose tumors are resistant or intolerant to standard treatments, aiming to better understand this new drugs potential. The study includes two parts dose escalation to find the maximum tolerated dose and dose expansion to determine the recommended dose for further research. Participants will receive AK138D1 through intravenous infusions at pre-determined dose levels based on their study group. The first part focuses on gradually increasing doses to identify safe limits, while the second part treats more patients with the recommended dose to further assess safety and early effectiveness. This process helps define appropriate dosing for future studies. During the trial, participants will undergo regular monitoring for side effects and dose-related toxicities for up to two years. Researchers will perform scans and measurements to track tumor response using standard criteria and collect blood samples to study drug levels, immune reactions, and survival outcomes. The study also tracks how long participants respond to treatment and how long they live without disease progression, providing a comprehensive view of safety and preliminary benefits over time.

Age: 18Years - 75YearsAll GendersPhase 1
4 locations
E

Actively Recruiting

Researchers are evaluating CS5007, a new EGFR and HER3 bispecific antibody-drug conjugate, in adults with advanced solid tumors that cannot be surgically removed. This first-in-human, open-label Phase I trial is designed to assess the safety, tolerability, how the drug moves through the body, and initial anti-tumor effects. The study includes two parts a dose escalation phase to find safe dose levels and a dose expansion phase to further assess the drug at recommended doses. Participants will receive CS5007 through intravenous infusion on Day 1 of repeated 21-day cycles. During the dose escalation phase, doses will gradually increase to determine the maximum tolerated dose and recommended Phase II dose. In the dose expansion phase, participants will receive the recommended doses based on earlier results. Treatment will continue with regular cycles while monitoring effects and side effects. Throughout the study, participants will undergo scheduled visits including laboratory tests, tumor assessments, and safety monitoring for up to about two years. Researchers will measure outcomes such as maximum tolerated dose, adverse events, tumor response by RECIST criteria, and pharmacokinetic parameters of CS5007. Participants are expected to comply with study procedures and receive ongoing evaluation to monitor the drugs effects and safety during this time.

Age: 18Years +All GendersPhase 1
7 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
S

Actively Recruiting

Researchers are evaluating BGB-26808, a HPK1 inhibitor, alone or combined with tislelizumab, an anti-PD-1 antibody, in adults with advanced solid tumors. This phase 1 trial aims to find the recommended dose for BGB-26808 and to assess its safety, tolerability, and preliminary antitumor effects. The study is open-label, nonrandomized in dose escalation, and later includes dose expansion phases.

Age: 18Years +All GendersPhase 1
28 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and tolerability of an experimental drug called DM005 in patients with advanced solid tumors. This first-in-human, open-label study aims to understand how DM005, a bispecific antibody-drug conjugate targeting c-MET and EGFR, behaves in the body and its preliminary impact on tumor response. Participants must have advanced solid malignant tumors that are not curable by standard local therapies and have progressed on or are intolerant to standard treatments. Participants receive DM005 intravenously on Day 1 of each 21-day cycle. The initial infusion lasts about 60 minutes, and if no infusion-related reactions occur, subsequent infusions may be shortened to about 30 minutes. The study includes a screening period of up to 28 days, followed by multiple treatment cycles, an end-of-treatment visit within 7 days after the last dose, and a follow-up visit about 30 days later. Dose escalation and expansion allow assessment of different dose levels to determine the maximum tolerated dose. During the study, participants will undergo safety evaluations, pharmacokinetic testing, and tumor assessments using RECIST criteria to measure treatment response. Researchers monitor dose-limiting toxicities and other safety data throughout the study. The primary outcomes focus on safety and determining the highest safe dose. Participants can expect regular visits for infusions and assessments over the treatment period, with follow-up visits to monitor ongoing effects, lasting up to 12 months for outcome evaluations.

Age: 18Years +All GendersPhase 1Phase 2
6 locations
O

Actively Recruiting

Researchers are studying the safety, tolerability, and preliminary anti-tumor effects of oral GFH276 combined with cetuximab or standard chemotherapy in adults with locally advanced or metastatic RAS-mutated solid tumors and pancreatic ductal adenocarcinoma PDAC. This open-label, multicenter Phase IbII trial aims to find the best dose for further study and evaluate treatment outcomes in this patient group. Participants will be assigned to one of three treatment groups GFH276 with cetuximab given intravenously every two weeks, GFH276 with nab-paclitaxel plus gemcitabine on cycles of three or four weeks, or GFH276 with mFOLFIRINOX chemotherapy given every two weeks. The Phase Ib stage involves increasing GFH276 doses to identify dose-limiting toxicities and safety, followed by Phase II expansion to assess anti-tumor effectiveness and long-term safety of each combination. During the study, participants will undergo tumor imaging, laboratory tests, adverse event monitoring, and blood sampling to study drug levels. Treatment continues until disease worsens, unacceptable side effects occur, consent is withdrawn, or the study ends. Safety and response will be followed for up to 24 months, with detailed assessments of adverse events, tumor response, and pharmacokinetics included.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
R

Actively Recruiting

Researchers are studying whether adding JNJ-90301900 to standard treatment with platinum-based chemotherapy and radiation therapy, followed by consolidation immunotherapy, can improve the rate of tumor shrinkage in people with locally advanced, unresectable stage III non-small cell lung cancer. This is a phase 2 randomized trial aiming to assess the feasibility, safety, and effectiveness of JNJ-90301900 injections combined with the usual treatments. Participants are randomly assigned to receive JNJ-90301900 injected directly into tumors or lymph nodes at different doses along with concurrent chemotherapy and radiation therapy, followed by immunotherapy with durvalumab. Another group receives the standard concurrent chemoradiation followed by durvalumab without JNJ-90301900 to compare outcomes. Chemotherapy includes carboplatin and paclitaxel delivered intravenously, and radiation is given by intensity modulated radiation therapy. Throughout the study, participants undergo assessments of tumor response using imaging and clinical evaluations over up to two years. Researchers monitor safety through physical exams, lab tests, and recording adverse events. The main outcome is the objective response rate, measuring how many participants experience tumor shrinkage. Secondary outcomes include progression-free survival, duration of response, and other disease control measures. Participants will be followed for up to two years and two months to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 2
45 locations

1-10 of 24

1